Project description:
In a recent Phase 2a controlled human malaria infection trial, healthy adult volunteers vaccinated with a delayed fractional dose regimen showed a higher vaccine efficacy (86.7%) than those receiving the standard dose regimen (62.5%).
The MAL094 study is designed to confirm these CHMI results in people living in malaria-endemic regions in Africa and against natural malaria infections. The study is being conducted at sites in Ghana and Kenya in children aged 5 to 17 months at enrollment.
Related resources:
Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garçon N, Krzych U, Marchand M. RTS,S Malaria Vaccine Evaluation Group.
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria.
New England Journal of Medicine. 1997;336(2):86-91.
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria.
New England Journal of Medicine. 1997;336(2):86-91.
Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, et al.
Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a Phase 2a controlled human malaria infection and immunogenicity study.
Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a Phase 2a controlled human malaria infection and immunogenicity study.
The Journal of Infectious Diseases. 2016;214(5):762–771.